![Pharmaceuticals | Free Full-Text | Myocardial Opioid Receptors in Conditioning and Cytoprotection | HTML Pharmaceuticals | Free Full-Text | Myocardial Opioid Receptors in Conditioning and Cytoprotection | HTML](https://www.mdpi.com/pharmaceuticals/pharmaceuticals-04-00470/article_deploy/html/images/pharmaceuticals-04-00470f1.png)
Pharmaceuticals | Free Full-Text | Myocardial Opioid Receptors in Conditioning and Cytoprotection | HTML
![Signaling Properties of Structurally Diverse Kappa Opioid Receptor Ligands: Toward in Vitro Models of in Vivo Responses | ACS Chemical Neuroscience Signaling Properties of Structurally Diverse Kappa Opioid Receptor Ligands: Toward in Vitro Models of in Vivo Responses | ACS Chemical Neuroscience](https://pubs.acs.org/cms/10.1021/acschemneuro.9b00195/asset/images/medium/cn-2019-00195v_0008.gif)
Signaling Properties of Structurally Diverse Kappa Opioid Receptor Ligands: Toward in Vitro Models of in Vivo Responses | ACS Chemical Neuroscience
![Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists](https://www.frontiersin.org/files/Articles/447554/fphar-10-00407-HTML/image_m/fphar-10-00407-g001.jpg)
Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists
![Topical administration of the kappa opioid receptor agonist nalfurafine suppresses corneal neovascularization and inflammation | Scientific Reports Topical administration of the kappa opioid receptor agonist nalfurafine suppresses corneal neovascularization and inflammation | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-021-88118-6/MediaObjects/41598_2021_88118_Fig7_HTML.png)
Topical administration of the kappa opioid receptor agonist nalfurafine suppresses corneal neovascularization and inflammation | Scientific Reports
![The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence - Biological Psychiatry The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence - Biological Psychiatry](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/41f7705e-1cce-421f-95db-2a80a3f1edd3/gr1.jpg)
The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence - Biological Psychiatry
![The blocking of kappa‐opioid receptor reverses the changes in dorsolateral striatum dopamine dynamics during the amphetamine sensitization - Azocar - 2019 - Journal of Neurochemistry - Wiley Online Library The blocking of kappa‐opioid receptor reverses the changes in dorsolateral striatum dopamine dynamics during the amphetamine sensitization - Azocar - 2019 - Journal of Neurochemistry - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/949a9b01-3f7c-4aa7-bc00-2e80cd815320/jnc14612-fig-0005-m.jpg)
The blocking of kappa‐opioid receptor reverses the changes in dorsolateral striatum dopamine dynamics during the amphetamine sensitization - Azocar - 2019 - Journal of Neurochemistry - Wiley Online Library
![Regulation of κ-Opioid Receptor Signaling in Peripheral Sensory Neurons In Vitro and In Vivo | Journal of Pharmacology and Experimental Therapeutics Regulation of κ-Opioid Receptor Signaling in Peripheral Sensory Neurons In Vitro and In Vivo | Journal of Pharmacology and Experimental Therapeutics](https://jpet.aspetjournals.org/content/jpet/338/1/92/F9.large.jpg)
Regulation of κ-Opioid Receptor Signaling in Peripheral Sensory Neurons In Vitro and In Vivo | Journal of Pharmacology and Experimental Therapeutics
![Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: A review of basic science and clinical implications - JAAD International Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: A review of basic science and clinical implications - JAAD International](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/d7e9437a-10fe-4493-bb0a-b928662d11bd/gr1.jpg)